4.5 Article

Safety, Pharmacokinetic, and Efficacy Studies of Oral DB868 in a First Stage Vervet Monkey Model of Human African Trypanosomiasis

Related references

Note: Only part of the references are listed.
Article Pharmacology & Pharmacy

Antiparasitic agents: new drugs on the horizon

Pascal Maeser et al.

CURRENT OPINION IN PHARMACOLOGY (2012)

Review Microbiology

Development of novel drugs for human African trypanosomiasis

Reto Brun et al.

FUTURE MICROBIOLOGY (2011)

Article Pharmacology & Pharmacy

Mechanisms Underlying Differences in Systemic Exposure of Structurally Similar Active Metabolites: Comparison of Two Preclinical Hepatic Models

Grace Zhixia Yan et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)

Article Microbiology

Novel Arylimidamides for Treatment of Visceral Leishmaniasis

Michael Zhuo Wang et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)

Article Medicine, General & Internal

Human African trypanosomiasis

Reto Brun et al.

LANCET (2010)

Article Infectious Diseases

Focus-Specific Clinical Profiles in Human African Trypanosomiasis Caused by Trypanosoma brucei rhodesiense

Lorna M. MacLean et al.

PLOS NEGLECTED TROPICAL DISEASES (2010)

Letter Immunology

Human African Trypanosomiasis in Areas without Surveillance

Francois Chappuis et al.

EMERGING INFECTIOUS DISEASES (2010)

Review Biochemistry & Molecular Biology

Antiparasitic compounds that target DNA

W. David Wilson et al.

BIOCHIMIE (2008)

Article Public, Environmental & Occupational Health

Quantifying the level of under-detection of Trypanosoma brucei rhodesiense sleeping sickness cases

M Odiit et al.

TROPICAL MEDICINE & INTERNATIONAL HEALTH (2005)

Article Medicine, Research & Experimental

Human African trypanosomiasis of the CNS: current issues and challenges

PGE Kennedy

JOURNAL OF CLINICAL INVESTIGATION (2004)

Article Chemistry, Medicinal

Synthesis and antiprotozoal activity of aza-analogues of furamidine

MA Ismail et al.

JOURNAL OF MEDICINAL CHEMISTRY (2003)